title: Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge.
abstract: Allergen specific nasal challenge (ASNC) is an optimal model to study the pathophysiological mechanisms sustaining allergic inflammation, particularly the cytokine pattern. Antihistamines have been accepted as a highly effective therapy for allergic rhinitis. The aim of this double blind, randomised, placebo controlled study was the evaluation of symptoms and cytokines, during the early phase, after a single dose of mizolastine (10 mg), fexofenadine (120 mg) or placebo, using the model of ASNC. A total of 30 patients with allergic rhinitis underwent nasal challenge 6 hours after treatment. The following parameters were evaluated 30 minutes after ASNC (i.e. early phase): nasal symptoms (rhinorrhea, itching, sneezing, obstruction), and cytokine pattern, including IL1, IL6, and TNFalpha. Mizolastine was associated with early phase reduction of: i) clinical symptoms (p < 0.03), ii) cyotkine levels of IL1 (p = 0.003), IL6 (p < 0.007), and TNF_ (p < 0.003) in comparison with placebo group. Fexofenadine significantly inhibited IL6 (p < 0.004) and TNFalpha (p < 0.004) levels in comparison with placebo. The present findings demonstrate that mizolastine exerts a significant effect on early phase events, reducing symptoms and pro-inflammatory cytokines. Fexofenadine reduces TNFalpha and IL6 levels only. These effects appear to be clinical relevant for mizolastine.
authors.affiliation: San Martino Hospital, Genoa, Italy.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Ciprandi
authors.forename: Ignazio
authors.initials: I
authors.lastname: Cirillo
authors.forename: Andrea
authors.initials: A
authors.lastname: Vizzaccaro
mesh_terms: D000328:Adult; D000485:Allergens; D018926:Anti-Allergic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D016207:Cytokines / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D009299:Nasal Provocation Tests; D032403:Parietaria; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents; D001562:Benzimidazoles; D016207:Cytokines; D006634:Histamine H1 Antagonists; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; C076170:mizolastine; D016593:Terfenadine; C093230:fexofenadine